These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17607916)

  • 1. Resistance to chemotherapy in ovarian carcinoma.
    Lage H; Denkert C
    Recent Results Cancer Res; 2007; 176():51-60. PubMed ID: 17607916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival following the documentation of platinum and taxane resistance in ovarian cancer.
    Büyükçelik A; Yalçin B; Utkan G; Doruk H
    Gynecol Oncol; 2004 Dec; 95(3):774-5; author reply 775-6. PubMed ID: 15582006
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy.
    Kurzeder C; Sauer G; Deissler H
    Curr Cancer Drug Targets; 2006 May; 6(3):207-27. PubMed ID: 16712458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.
    Caponigro F; Willemse P; Sorio R; Floquet A; van Belle S; Demol J; Tambaro R; Comandini A; Capriati A; Adank S; Wanders J
    Invest New Drugs; 2005 Jan; 23(1):85-9. PubMed ID: 15528985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
    Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
    J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.
    Goto T; Takano M; Ohishi R; Iwasa N; Shimizu M; Hasegawa K; Nagao S; Fujiwara K
    J Obstet Gynaecol Res; 2010 Aug; 36(4):764-8. PubMed ID: 20666942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
    Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
    Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
    Matsuo K; Bond VK; Im DD; Rosenshein NB
    Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance.
    Pinato DJ; Graham J; Gabra H; Sharma R
    Cancer Treat Rev; 2013 Apr; 39(2):153-60. PubMed ID: 22595680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
    Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer.
    Liu J; Jiao X; Gao Q
    Drug Discov Today; 2020 Jul; 25(7):1232-1238. PubMed ID: 32360532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
    Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH
    Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine Clinical Practice for Patients With Recurrent Ovarian Carcinoma: Results From the TROCADERO Study.
    Freyer G; Ray-Coquard I; Fischer D; Martín AG; Kielhorn A; Chia V; Nanayakkara N; Taylor A
    Int J Gynecol Cancer; 2016 Feb; 26(2):240-7. PubMed ID: 26745696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of taxane resistance genes with the clinical course of ovarian carcinoma.
    Ehrlichova M; Mohelnikova-Duchonova B; Hrdy J; Brynychova V; Mrhalova M; Kodet R; Rob L; Pluta M; Gut I; Soucek P; Vaclavikova R
    Genomics; 2013 Aug; 102(2):96-101. PubMed ID: 23542236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ovarian cancer--therapeutic options after the failure of the first line of treatment].
    Jabłońska E; Chłosta M; Pawlega J
    Ginekol Pol; 2004 Jan; 75(1):58-64. PubMed ID: 15112475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Related-factor analysis on efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma].
    Cheng XD; Lü WG; Xie X; Huang XF; Ye DF; He HC; Ding ZM
    Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):670-2. PubMed ID: 14728853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy.
    Hanker LC; Loibl S; Burchardi N; Pfisterer J; Meier W; Pujade-Lauraine E; Ray-Coquard I; Sehouli J; Harter P; du Bois A;
    Ann Oncol; 2012 Oct; 23(10):2605-2612. PubMed ID: 22910840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.
    Marchetti C; Palaia I; De Felice F; Musella A; Donfracesco C; Vertechy L; Romito A; Piacenti I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
    Cancer Treat Rev; 2016 Jan; 42():41-6. PubMed ID: 26559739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.